Pharvaris N.V. (PHVS)
| Market Cap | 1.99B +99.2% |
| Revenue (ttm) | n/a |
| Net Income | -194.35M |
| EPS | -3.14 |
| Shares Out | 65.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 444,226 |
| Open | 30.34 |
| Previous Close | 30.70 |
| Day's Range | 29.36 - 30.43 |
| 52-Week Range | 15.34 - 33.33 |
| Beta | -2.33 |
| Analysts | Buy |
| Price Target | 45.40 (+49.2%) |
| Earnings Date | May 12, 2026 |
About PHVS
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE a... [Read more]
Analyst Summary
According to 10 analysts, the average rating for PHVS stock is "Buy." The 12-month stock price target is $45.4, which is an increase of 49.20% from the latest price.
News
Pharvaris price target raised to $33 from $31 at BofA
BofA raised the firm’s price target on Pharvaris (PHVS) to $33 from $31 and keeps a Neutral rating on the shares after having hosted CFO David Nassif for a fireside…
Pharvaris Transcript: Bank of America Global Healthcare Conference 2026
Raised €132M to fund launches through 2028, with ODT NDA filing and Prophy data readout expected in 2026. RAPIDe-3 met all endpoints, showing rapid, durable efficacy. Commercial buildout targets 90 staff by 2027, aiming for leadership in both on-demand and prophylactic HAE markets.
Pharvaris price target lowered to $74 from $75 at Citizens
Citizens lowered the firm’s price target on Pharvaris (PHVS) to $74 from $75 and keeps an Outperform rating on the shares. The Phase 3 CHAPTER-3 readout in Q3 is the…
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
Cash and cash equivalents were EUR 247 million as of March 31, 2026, compared to EUR 292 million for December 31, 2025. “In 2026, Pharvaris (PHVS) remains focused on execution…
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand tre...
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help ...
Pharvaris price target raised to $31 from $30 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Pharvaris (PHVS) to $31 from $30 and keeps a Neutral rating on the shares. The firm updated the company’s model…
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help ...
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
Pharvaris (PHVS) presented data evaluating safety margins of administration of deucrictibant immediate-release, or IR, capsule in combination with deucrictibant extended-release, or XR, tablet at the ...
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne...
Pharvaris price target raised to $52 from $48 at JonesResearch
JonesResearch analyst Debanjana Chatterjee raised the firm’s price target on Pharvaris (PHVS) to $52 from $48 and keeps a Buy rating on the shares, citing an increased peak sales projection…
Pharvaris initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Pharvaris (PHVS) with an Outperform rating and $42 price target The firm is bullish on the company’s prophylactic data expected in Q3 and expects it…
Pharvaris price target raised to $42 from $41 at Wedbush
Wedbush raised the firm’s price target on Pharvaris (PHVS) to $42 from $41 and keeps an Outperform rating on the shares. Most important in the Q4 update, Pharvaris reiterated all…
Pharvaris price target lowered to $51 from $52 at RBC Capital
RBC Capital lowered the firm’s price target on Pharvaris (PHVS) to $51 from $52 and keeps an Outperform rating on the shares after its Q4 results. The firm continues to…
Pharvaris reports Q4 EPS (EUR 0.72) vs. (EUR 0.64) last year
“The positive readout of our first pivotal Phase 3 study, RAPIDe-3, at the end of 2025 was a crucial moment for Pharvaris (PHVS). With the momentum of this important milestone,…
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ZUG, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne...
Pharvaris announces publications of efficacy, safety evidence on deucrictibant
Pharvaris (PHVS) announced that two articles have been published back-to-back in the same issue of The Lancet Haematology. The articles detail data from the two randomized Phase 2 studies, CHAPTER-1…
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne...
Pharvaris Transcript: Leerink Global Healthcare Conference 2026
Strong RAPIDe-3 data supports NDA filing for acute HAE in H1, with prophy trial readout expected in Q3. Oral deucrictibant offers rapid symptom relief and unique flexibility for both on-demand and prophylactic use, positioning it well in a dynamic, growing market.
Pharvaris reports results from study of patient experience during HAE attacks
Pharvaris (PHVS) announced that results from a Pharvaris-sponsored non-interventional, mixed methods, real-world study assessing the patient experience during acute HAE attacks across alternative endp...
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne...
Pharvaris Transcript: The Citizens Life Sciences Conference 2026
The company is advancing oral therapies for hereditary and acquired angioedema, with strong phase III data for on-demand treatment and promising phase II results for prophylaxis. NDA filings and launches are planned, supported by a robust cash position and commercial infrastructure.
Pharvaris initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Pharvaris (PHVS) with an Outperform rating and $52 price target The firm believes the company’s deucrictibant can offer a “compelling profile” across the hereditary a...
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
ZUG, Switzerland, March 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne...
Pharvaris Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company is advancing an oral therapy for HAE, with phase III data showing rapid, robust efficacy in on-demand use and promising results in prophylaxis. NDA filing is planned for the first half of the year, with a strong cash runway and multiple data presentations at AAAAI.